Literature DB >> 7461877

The treatment of heroin addiction: naltrexone alone and with behavior therapy.

E J Callahan, R A Rawson, B McCleave, R Arias, M Glazer, R P Liberman.   

Abstract

Recently, narcotic antagonists (drugs which block the euphoric effects of opiates) and behavior therapy have both been proposed as possible treatments for heroin addiction. In the present study the effectiveness of one particular antagonist, naltrexone, was examined under two conditions: (1) when administered alone, and (2) when administered in conjunction with behavior therapy. Measures of treatment effect included number of days on naltrexone, number of weeks in the program, reported side effects, and number of dirty urines in each treatment. While data initially indicated a superiority of the combined treatment program, this superiority faded over time. Results are discussed in terms of program start-up effects (especially when using experimental drugs), terms of process versus outcome measurement, and in terms of societal pressure operating against the success of heroin treatment in minority populations with poor job skills.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7461877     DOI: 10.3109/10826088009040057

Source DB:  PubMed          Journal:  Int J Addict        ISSN: 0020-773X


  8 in total

1.  Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.

Authors:  Sandra D Comer; Warren K Bickel; Richard Yi; Harriet de Wit; Stephen T Higgins; Galen R Wenger; Chris-Ellyn Johanson; Mary Jeanne Kreek
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

2.  Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Authors:  Maria A Sullivan; Suzanne K Vosburg; Sandra D Comer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

Review 3.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

4.  Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?

Authors:  Maria A Sullivan; Adam Bisaga; John J Mariani; Andrew Glass; Frances R Levin; Sandra D Comer; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2013-07-01       Impact factor: 4.492

5.  Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants.

Authors:  Gary K Hulse; Robert J Tait; Sandra D Comer; Maria A Sullivan; Ian G Jacobs; Diane Arnold-Reed
Journal:  Drug Alcohol Depend       Date:  2005-09-01       Impact factor: 4.492

6.  Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

Authors:  Sandra D Comer; Maria A Sullivan; Elmer Yu; Jami L Rothenberg; Herbert D Kleber; Kyle Kampman; Charles Dackis; Charles P O'Brien
Journal:  Arch Gen Psychiatry       Date:  2006-02

Review 7.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

8.  Amphiphilic Block Copolymer Microspheres Derived from Castor Oil, Poly(ε-carpolactone), and Poly(ethylene glycol): Preparation, Characterization and Application in Naltrexone Drug Delivery.

Authors:  Maria Nerantzaki; Eirini Skoufa; Kyriakos-Vasileios Adam; Stavroula Nanaki; Apostolos Avgeropoulos; Margaritis Kostoglou; Dimitrios Bikiaris
Journal:  Materials (Basel)       Date:  2018-10-16       Impact factor: 3.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.